KGKeerti Gedela

Keerti Gedela

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Keerti Gedela has a total of 176 co-authors. Here are the top co-authors by number of shared publications:

  • Hendry Luis

    Yayasan Bali Peduli, Bali, Indonesia

    8 shared publications
  • Frank Stephen Wignall

    Yayasan Bali Peduli HIV/Sexual Health Clinic Denpasar Indonesia

    7 shared publications
  • Irwanto Irwanto

    HIV/AIDS Research Centre, Atma Jaya Catholic University, Jakarta, Indonesia

    7 shared publications
  • Alan McOwan

    Department of HIV/GUM, Chelsea & Westminster Hospital, National Health Service (NHS) Foundation Trust , London , United Kingdom

    5 shared publications
  • Evi Sukmaningrum

    Faculty of Psychology, Atma Jaya Catholic University of Indonesia, South Jakarta, DKI Jakarta, Indonesia

    5 shared publications
  • Louise Sigfrid

    Policy and Practice Research Group, Pandemic Sciences Institute, University of Oxford, Oxford, UK

    4 shared publications

Latest Publications

  • Open Access

    A Four‐Item Risk Score to Target Acute HIV Infection Testing Among Men Who Have Sex With Men in Indonesia: Development and Validation in the INTERACT Prospective Cohort

    by Gilbert Lazarus, Nurhayati H. Kawi, Hendry Luis, Dwi P. Rahmawati, Erik P. Sihotang, Margareta Oktaviani, Pande Putu Januraga, Suwarti, Evi Sukmaningrum, Evy Yunihastuti, et al.

    Introduction: Indonesia has an escalated HIV epidemic among key populations, especially men who have sex with men (MSM). Diagnosis and immediate treatment of acute HIV infection (AHI), the earliest phase with the highest transmission risk, is beneficial for individual health and can reduce onward transmission. To inform whom to test for possible AHI using targeted, risk‐stratified HIV‐PCR testing, this study evaluated the performance of the validated, seven‐item Amsterdam AHI risk score among Indonesian MSM, and developed a locally optimized score. Methods: We used the INTERACT prospective cohort of MSM (≥16 years) attending sexual health clinics in Jakarta and Bali (May 2023−February 2025) who were tested with add‐on Xpert HIV‐PCR (Cepheid) if their HIV antibody rapid testing was negative or inconclusive. We used generalized estimating equation models to generate risk scores, combining symptoms, risk factors and socio‐demographics. The optimized risk score was internally validated using bootstrap resampling. We calculated area under the curve (AUC), sensitivity and specificity (ISRCTN41396071). Results: Among 1887 individuals, 20 were diagnosed with AHI, and 1867 tested AHI negative across 3446 test visits. The Amsterdam score yielded an AUC of 0.82 (95% CI 0.75−0.90) with a sensitivity of 85.0% (64.0%−94.8%) and a specificity of 59.2% (57.5−60.8). The optimized risk score included one symptom (fever <2 weeks), one risk factor (condomless receptive anal intercourse <6 months) and two socio‐demographic characteristics (age 16–30 years, not having received higher education), and achieved an AUC of 0.91 (0.87−0.96) with a sensitivity of 100% (83.9−100) and a specificity of 65.3% (63.6%−66.8%). Internal validation yielded an AUC of 0.86 (0.67−0.97). Applying this risk score would classify 35.1% of MSM as eligible for add‐on HIV‐PCR testing, identifying 83.9%–100% of individuals who have AHI. Conclusions: This four‐item risk score of easily collected variables can facilitate efficient AHI detection in high‐yield clinic settings, enhancing opportunities for HIV prevention. In the Indonesian context, younger MSM with lower educational attainment were particularly vulnerable to AHI.

  • Open Access

    Chikungunya clinical management guidance: insights from a health system stakeholder study in Indonesia

    by Evi Sukmaningrum, Komang Ayu Kartika Sari, Theresia Puspoarum Kusumoputri, Ni Luh Putu Ariastuti, Kevin Kristian, Eric Sindunata, Hendry Luis, Pande Putu Januraga, Peter W Horby, Louise Sigfrid, et al.

    Chikungunya virus poses a significant public health challenge in Indonesia. Robust surveillance and diagnostics are lacking, and clinical management guidelines (CMGs) are absent. This practice article draws on insights from a qualitative health system stakeholder study conducted in Jakarta and Bali, Indonesia. The study examined barriers to the development and implementation of chikungunya CMGs. Findings reveal critical gaps in knowledge, diagnostic tools and prioritisation, exacerbated by systemic decentralisation and resource limitations. Robust, locally adapted CMGs could address these gaps, enhance clinical care and improve outbreak preparedness. This study underscores the importance of stakeholder engagement and capacity building in developing CMGs, offering lessons for low-resource settings managing emerging diseases.

  • Open Access

    Incorporating acute HIV infection screening, same‐day diagnosis and antiretroviral treatment into routine services for key populations at sexual health clinics in Indonesia: a baseline analysis of the INTERACT prospective study

    by Irwanto Irwanto, Nurhayati H. Kawi, Hendry Luis, Dwi P. Rahmawati, Erik P. Sihotang, Pande Putu Januraga, Margareta Oktaviani, Suwarti Suwarti, Gilbert Lazarus, Evi Sukmaningrum, et al.

    Introduction: Indonesia has an escalated HIV epidemic concentrated among key populations. To strengthen the care cascade, we implemented a care pathway for the screening of individuals for acute HIV infection (AHI), to achieve prompt diagnosis and antiretroviral treatment (ART) initiation, at three non‐governmental sexual health clinics in Jakarta and Bali. We assessed the AHI testing uptake, yield and prevalence, and the care cascade.Methods: This is a cross‐sectional baseline analysis of individuals (≥16 years) who presented for HIV testing and were consecutively enrolled (May 2023−November 2024). We used an AHI risk‐score self‐assessment and test algorithm comprising a fourth‐generation antibody/p24 antigen rapid diagnostic test (4gRDT; Abbott Determine HIV Early Detect) and, if negative/discordant, followed by HIV‐PCR (Cepheid Xpert) (either individual or pooled‐sample testing). AHI was pragmatically defined as having negative/discordant RDT results with positive HIV‐PCR (ISRCTN41396071).Results: Three thousand seven hundred and ninety‐seven (44.0%) of 8665 individuals were screened for study eligibility, and 3689 (97.2%) were enrolled. Median age was 28 years, and 78.2% were male. Men who have sex with men (MSM) accounted for 53.3%, clients of sex workers 19.2%, persons having a sex partner living with HIV 8.9% and sex workers 4.1%. We diagnosed 229 (6.3%; 229/3662) persons with RDT‐positive (chronic) HIV, and we additionally identified 13 persons with AHI—that is a diagnostic yield of 5.6% (95% CI 3.1−9.5; 13/229) overall, and 6.1% (95% CI 3.2−10.3; 12/198) among MSM. AHI prevalence was 0.38% (95% CI 0.20−0.65; 13/3429) overall, and 0.72% (95% CI 0.37−1.2; 12/1677) among MSM. The number of persons needed to test to identify one person with AHI was 264 (3429/13) overall and 140 (1677/12) among MSM. The 4gRDT's performance to detect AHI was poor (2/13). Most participants received their HIV‐PCR results on the same day (84.8%, 2907/3429) or within 24 hours (92.8%, 3182/3429). Of the 242 newly HIV‐diagnosed individuals, 236 (97.5%) started ART, of whom 158 (67.0%) on the same day and 215 (91.1%) within 1 week.Conclusions: We successfully implemented prompt AHI diagnosis and treatment, and identified a high AHI prevalence among Indonesian MSM. Prioritizing access to AHI testing can create opportunities for enhanced interventions to curb the HIV epidemic among key populations.


  • Open Access

    Embedding equity, diversity and inclusion processes within clinical trials and health and social care research

    by Keerti Gedela, Richard Wong, Suki Balendra, Sunder Chita, Helen Jones, Rainer Golombek, Keitumetse-Kabelo Murray

    The lack of diverse and inclusive clinical research populations fuels health inequalities in the UK, and there is an urgent need to reverse this. This communication provides a practical framework for positive action to integrate equity, diversity and inclusion (EDI) processes into clinical research design, protocols and implementation and to establish accountable clinical research systems that are trustworthy to the public and accessible to diverse communities. This framework is a consensus-based guide developed by the Equality, Diversity and Inclusion working group of the National Institute for Health and Care Research’s (NIHR’s) Clinical Research Network in North West London. This work involved analysing challenges to integrating EDI within the clinical research process, such as clinical trial protocols as directed by industry sponsors and National Health Service investigator teams. It aligns with the UK government’s clinical research strategy and NIHR’s INCLUDE project. It advises an interconnected approach to embedding EDI throughout the clinical research lifecycle. By following this framework, we aspire to guide clinical research towards a more equitable, inclusive and representative model that better serves the needs of all populations.


  • Open Access

    Factors impacting on the implementation of clinical management guidelines (CMGs) for high consequence infectious diseases (HCIDs) during outbreaks globally: a systematic review

    by Dania Talaat Dahmash, Melina Michelen, Ishmeala Rigby, Helen Piotrowski Piotrowski, Robert Nartowski, Vincent Cheng, Andrew Dagens, Eli Harriss, Peter Hart, Shevin T Jacob, et al.

    Background: High consequence infectious disease (HCID) outbreaks are a threat to societies globally. Evidence-based clinical management guidelines (CMGs) are important tools for translating evidence into clinical practice. However, developing guidelines is resource-intensive and guidelines must remain responsive to new evidence while being accessible to clinicians. This review aims to identify factors that impact the implementation of HCID CMGs across different contexts during health emergencies. Methods: A systematic review. Four databases (Ovid MEDLINE, Ovid Embase, Ovid Global Health, and Scopus) were searched until November 2021, complemented by a grey literature search conducted on November 2021. Studies that explored implementation of HCID guidelines were included, without language restriction. Two reviewers screened articles and extracted data. Data was analysed using qualitative inductive thematic analysis. Results: Of 12,512 records, 28 studies were included, with most (61%, 17/28) set in high-income countries. Three overarching themes impacting HCID CMG implementation were identified: 1) Development and characteristics of CMGs, 2) Organisational and logistical factors, and 3) Realities of Implementing guidelines. Key recommendations included engaging all relevant representatives in CMG development, including those in endemic countries; integrating mechanisms for regular updates; supporting implementation by ensuring access to necessary resources (e.g., equipment, pharmaceuticals), and training; and enabling intra- and inter-organisational collaboration and communication channels. Importantly, recognising the challenges faced by staff in implementing new guidance is crucial, as is understanding the impact of a supportive environment on the effective implementation of care during emergencies. Conclusion: These findings highlight the need to bridge the gap between HCID CMGs development and their real-world implementation amid health emergencies. The complex factors impacting effective implementation should be addressed beginning at the development stage, with training focused on implementation during inter-epidemic times, and ongoing implementation monitored during outbreaks. Further research to guide implementation frameworks are recommended. Key messages of the article: What is already known on this topic: - Clinical management guidelines (CMGs) are important tools to guide clinical decision-making and optimise care and outcome. - The COVID-19 pandemic showcased the need for CMGs to be rapidly responsive to new emerging evidence. - HCID CMGs are scarce and often of low quality, and when available they frequently contain inconsistent therapeutic recommendations. - Most CMGs are developed by high-income countries while the burden is often the largest in resource deprived settings. What this study adds: - This study highlights the gap between HCID CMGs development and their implementation in real world within emergency setting. - The review explores the potential factors that influence the implementation process of HCID CMGs such as time, information and resource constraints. - Key recommendations to stakeholder and CMGs developers were explored within this study such as the use of “living guidelines” to make CMGs updates more efficient, and the availability of viable alternative options for different-resourced healthcare settings to bridge the gap between the ideal situation and the local realities. - There is a need for a clear communication and consensus on HCP expectations and obligations during health emergencies within CMGs as well as the practicalities of delivering training during emergencies need to be addressed within CMG development and implementation. How this study might affect research, practice or policy: - HCID implementation research should consider these factors impacting effective implementation when planning, from the development stage through ongoing monitoring. - Further research and funds are needed to guide implementation frameworks.

  • Open Access

    Implementing a clinical pathway for diagnosing and treating acute HIV infection among key populations attending sexual health clinics in Indonesia: cohort profile of the INTERACT study

    by Irwanto, Nurhayati H. Kawi, Hendry Luis, Erik P. Sihotang, Pande Putu Januraga, Margareta Oktaviani, Suwarti, Dwi Prasetyaning Rahmawati, Evi Sukmaningrum, Evy Yanihastuti, et al.

    Background: To reduce the high HIV incidence among key populations in Indonesia, we implemented a clinical pathway for screening, diagnosis and treatment of acute HIV infection (AHI) in sexual health clinics in Jakarta and Bali. This paper presents a cohort profile and analysis of baseline data on the study uptake, diagnostic yield, and estimated AHI prevalence and screening cascade outcomes. Methods: We performed a baseline analysis of 1879 individuals who underwent AHI screening at three sexual health clinics in Jakarta and Bali between May and December 2023, comprising a risk-score assessment, fourth-generation antibody/p24 antigen-based rapid diagnostic test (RDT; Abbott Determine HIV Early Detect) and HIV-PCR (Xpert) testing. Results: Median age was 27 years (IQR24-31), and 75.4% were male. Men who have sex with men (MSM) accounted for 50.4%, clients of sex workers 20.1%, and sex workers 5.2%. Of 1866 participants tested at study enrolment, 113 (6.1% [113/1866]) had chronic HIV (antibody-positive) and 6 (0.34% [6/1748]) had AEHI. HIV-PCR testing led to a 5.3% (95%CI1.9-11.2) increase in confirmed HIV diagnoses. The number needed to test to detect one AEHI case was 291 (1748/6) overall and 169 (842/5) among MSM. Overall HIV and AHI prevalence was 6.4% (95%CI 5.3-7.6; 119/1866) and 0.34% (95%CI0.12-0.74; 6/1748) overall; and 10.8% (95%CI8.9-13.0; 102/940) and 0.53% (95%CI 0.17-1.2; 5/940) among MSM. The Abbott Determine HIV Early Detect RDT only detected 2 (18.2%) of 11 AEHI cases. 113 (95.0%) newly diagnosed individuals were linked to care and started ART, of whom 75 (66.4%) on the same day and 104 (92.0%) within a week (median 0 days, range 0-93). Conclusion: AHI screening, diagnosis and prompt treatment is feasible among high-risk urban MSM in Indonesia. Further evaluations are needed to estimate clinical impact and cost-effectiveness of AHI screening in this setting. The study continues accrual and follow-up, and provides a platform for future immuno-virological, social science, and intervention studies in Indonesia.


  • Open Access

    An evaluation of global Chikungunya clinical management guidelines: A systematic review

    by Eika Webb, Melina Michelen, Ishmeala Rigby, Andrew Dagens, Dania Dahmash, Vincent Cheng, Reena Joseph, Samuel Lipworth, Eli Harriss, Erhui Cai, et al.


  • Infectious Proctitis due to Human Mpox

    by Keerti Gedela, Dayana Da Silva Fontoura, Alex Salam, Gerry Gorman, John Golden, Geraldine O’hara, Ahmed Elowaidy, Victoria Tittle, Nicolo Girometti, Gary Whitlock, et al.

    We describe 2 cases of infectious proctitis secondary to human monkeypox in patients presenting with rectal pain. These cases highlight the importance of multidisciplinary management of monkeypox and in expanding case definitions and enabling clinical recognition in patients presenting without skin rash.


  • Open Access

    Availability, scope, and quality of monkeypox clinical management guidelines globally: a systematic review

    by Eika Webb, Ishmeala Rigby, Melina Michelen, Andrew Dagens, Vincent Cheng, Amanda Rojek, Dania Dahmash, Susan Khader, Keerti Gedela, Alice Norton, et al.

    Background: Monkeypox (MPX) is an important human orthopoxvirus infection. There has been an increase in MPX cases and outbreaks in endemic and non-endemic regions in recent decades. We appraised the availability, scope, quality, and inclusivity of clinical management guidelines for MPX globally. Methods: For this systematic review, we searched six databases from inception until 14 Oct. 2021, augmented by a grey literature search until 17 May 2022. MPX guidelines providing treatment and supportive care recommendations were included, with no exclusions for language. Two reviewers assessed the guidelines. Quality was assessed using the Appraisal of Guidelines for Research and Evaluation (AGREE) II tool. Results: Of 2026 records screened, 14 guidelines were included. Overall, most guidelines were of low-quality with a median score of 2 out of 7 (range: 1-7), lacked detail and covered a narrow range of topics. Most guidelines focused on adults, five (36%) provided some advice for children, three (21%) for pregnant women, and three (21%) for people living with HIV. Treatment guidance was mostly limited to advise on antivirals; seven guidelines advised cidofovir (four specified for severe MPX only); 29% (4/14) tecovirimat, and 7% (1/14) brincidofovir. Only one guideline provided recommendations on supportive care and treatment of complications. All guidelines recommended vaccination as post-exposure prophylaxis (PEP). Three guidelines advised on vaccinia immune globulin as PEP for severe cases in people with immunosuppression. Conclusion: Our results highlight a concerning lack of evidence-based clinical management guidelines for MPX globally. There is a clear and urgent need for research into treatment and prophylaxis including for different risk populations. The current outbreak provides an opportunity to accelerate this research through coordinated high-quality studies. New evidence should be incorporated into globally accessible guidelines, to benefit patient and epidemic outcomes. A ‘living guideline’ framework is recommended. Systematic review registration: PROSPERO CRD42020167361 Funding statement: This work was supported by the UK Foreign, Commonwealth and Development Office and Wellcome [215091/Z/18/Z] and the Bill & Melinda Gates Foundation [OPP1209135].

  • Immediate PrEP when accessing PEP: A service evaluation

    by Beatrice Cockbain, Gary Whitlock, Alan McOwan, Sheel Patel, Diarmuid Nugent, Nicolo Girometti, Tara Suchak, Keerti Gedela, Vicky Tittle, the Dean Street Collaborative Group

    Objectives In January 2021, 56 Dean Street, a London sexual health clinic, changed clinic policy so that all those attending for post-exposure prophylaxis (PEP) were offered quick-start opt-out pre-exposure prophylaxis (PrEP) following completion of the 28-day PEP course. We assessed the uptake of this quick-start PrEP in service users attending for PEP. Methods We undertook a case note review of those who received PEP during the 2-week period from 17 February to 1 March 2021, assessing the data and comparing them to those from the same period in 2020 (15 February-28 February 2020) before quick-start opt-out PrEP was introduced. Results The number of service users receiving PEP was 82 in 2020 and 42 in 2021, of which an unmet PrEP need was demonstrated in 81.7% (67/82) in 2020 and 78.6% (33/42) in 2021 (p = 0.8106). Of those with an unmet need, a higher proportion (97.0% [32/33]) were offered PrEP in 2021 following the introduction of opt-out PrEP compared with the 85.1% (57/67) in 2020 (p = 0.0953). Of those eligible for PrEP who were offered it during their PEP consultation, 53.1% (17/32) in 2021 were dispensed PrEP compared with 17.5% (10/57) in 2020 (p = 0.0007). Conclusion Since the introduction of quick-start opt-out PrEP, uptake in eligible candidates increased from 17.5% to 53.1%. This suggests that this strategy was acceptable to service users.